To access this element change to forms mode OFF
Grant Award View - GA218188
nanoIMPAC: Monitoring immune toxicities and tumour immune evasion in...
GA ID:
GA218188
Agency:
Cancer Australia
Approval Date:
14-Feb-2022
Publish Date:
17-Feb-2022
Category:
Cancer
Grant Term:
1-Mar-2022 to 28-Feb-2025
Value (AUD):
$552,176.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 21/22 Improved cancer control
Grant Program:
2021 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
nanoIMPAC: Monitoring immune toxicities and tumour immune evasion in lung cancer
Purpose:
Immune evasion is a key driver of disease progression in lung cancer, contributing significantly to low survival rate in patients. Activating the immune system by immune checkpoint inhibition has led to therapy success but is often short-lived and overshadowed by immune toxicities. This project aims to test the diagnostic capability of a blood-based screening nanotechnology to detect early immune toxicities, immune evasion, and tumour recurrence to improve patient and treatment outcomes.
GO ID:
GO Title:
2021 Priority-driven Collaborative Cancer Research Scheme for funding commencing in 2022
Internal Reference ID:
2010799_Trau
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
The University of Queensland
Recipient ABN:
63 942 912 684
Grant Recipient Location
Suburb:
The University of Queensland
Town/City:
St Lucia
Postcode:
4072
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
QLD
Postcode:
4072
Country:
AUSTRALIA